A manufacturing facility each of drugmakers Dr. Reddy’s Laboratories and Divi’s Laboratories in Andhra Pradesh and Telangana respectively has concluded inspection by the U.S. Food and Drug Administration (U.S. FDA) without any observations.
The active pharmaceutical ingredient (API) facility (CTO-SEZ) of Dr. Reddy’s in Srikakulam was inspected between November 10 and November 14, 2025. It was a GMP inspection and concluded with zero observations, the company said in a filing on Friday. Dr. Reddy’s shares closed less than 1% lower at ₹1,244.95 each on the BSE.
In a filing on the inspection of its unit, Divi’s Laboratories said the Unit-I facility located in Yadadri Bhuvanagiri district of Telangana was inspected by U.S. FDA from November 10-14. The inspection was a general cGMP inspection and concluded with no Form 483 observations. The company’s shares closed 1.19% lower at ₹6,511.40 each.
Published – November 14, 2025 10:10 pm IST
